ARS Pharmaceuticals, Inc. (SPRY): Total Assets
$327.65M
As of 2025-12-31
$249.50M
As of 2026-06-30
+5.2%
3-year compound annual growth
-3.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $327.65M | -6.7% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $351.15M | +50.6% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $233.19M | -17.1% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $281.44M | +358.0% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $61.45M | -84.4% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $394.80M | n/a | 2022-03-31, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $327.65M | -6.7% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $688.13M | +2.8% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $567.75M | -7.3% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $271.15M | -21.2% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $323.15M | +0.4% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $1.42B | +1.6% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $92.11M | +21.0% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $151.57M | +25.7% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $1.36B | -0.3% |
Compare SPRY, NRIX, LAB, ARCT side by side · Screen every company in Pharmaceutical Preparations ↗